Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2012 Financial Results
Date:3/1/2013

INCLINE VILLAGE, Nev., March 1, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Total revenues in 2012 were $374.5 million, compared to $362.0 million in 2011, with royalty revenues increasing seven percent over full year 2011. For the fourth quarter of 2012, total revenues were $86.0 million, compared to $72.8 million in the fourth quarter of 2011.

Royalty revenues for the fourth quarter of 2012 are based on third quarter product sales by PDL's licensees. The fourth quarter 2012 revenue growth was primarily driven by increased royalties from third quarter 2012 sales of Herceptin® and Avastin®, which are marketed by Genentech and Roche.  Royalty revenue for the fourth quarter and 2012 are net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.

Operating expenses in 2012 were $25.5 million, compared with $18.3 million in 2011. For the fourth quarter of 2012, general and administrative expenses were $7.7 million compared with $4.8 million for the same period of 2011.

Net income in 2012 was $211.7 million, or $1.45 per diluted share as compared with net income of $199.4 million in 2011 or $1.15 per diluted share. Net income for the fourth quarter of 2012 was $49.4 million or $0.34 per diluted share as compared with net income of $38.9 million or $0.24 per diluted share for the same period of 2011.

Net cash provided by operating activities in 2012 was $210.2 million, compared with $169.8 million in 2011. At December 31, 2012, PDL had cash, cash equivalents and investments of $148.7 million, compared with $227.9 million at
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  The National Association of Drug Diversion Investigators ... Kentucky,s real-time, stop-sale pseudoephedrine ... Precursor Log Exchange (NPLEx) system automatically blocks unlawful ... helps flag meth offenders for law enforcement. Police ... "watch lists" that notify them via email when ...
(Date:10/25/2014)... , Oct. 24, 2014   Metanome, Inc. , ... metagenomic services and data analysis, was the genomic sequencing ... ) Phase I/II clinical trial of SER 109, an ... Clostridium difficile infections (CDI). Metanome ... Health,s R&D and clinical programs. Such genomic characterization has ...
(Date:10/25/2014)... October 24, 2014 ... has announced the addition of the  "Global ...  report to their offering.  ... Chinese Acne Medication Industry Report 2014 is ... current state of the global acne medication ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3
... , SAN DIEGO, Sept. 11 Calixa ... development and commercialization of novel antibiotics for the treatment ... in 20 posters at the Interscience Conference on Antimicrobial ... San Francisco on September 12 to 15, 2009. ...
... , , , ... preliminary schedule of events at the Cardiovascular Research Foundation,s (CRF) ... September 21st to Friday, September 25th, in San Francisco, CA. ... the world,s largest events for those performing cardiac diagnostics and ...
Cached Medicine Technology:Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundation's (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting 2
(Date:10/25/2014)... 26, 2014 Top 10 Best SEO ... the world. The site has recently compared many hosting ... HostMonster are among the most reliable Linux web hosting ... Top 10 Best SEO Hosting says, “The hosting suppliers ... companies who outperform their competitors on hosting features, uptime ...
(Date:10/25/2014)... The global HCIT outsourcing market is ... reach $50.4 billion by 2018 from $35 billion in ... pharmaceutical industry are driving the HCIT outsourcing market. These ... focus on core business, reduce operational and maintenance costs, ... reducing hiring and training costs), share risk, and quickly ...
(Date:10/25/2014)... The Wehrman Collaborative, LLC ... for disabled users by disabled users, has granted ... Mackin Educational Resources of Burnsville, Minnesota, for their ... to the Minnesota Alliance for Patient Safety of ... website. Both organizations have met WeCo’s ...
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Researchers who discovered antibiotics ... are cause for concern. The use of ... for human consumption contribute to the development of ... background information from the study. Each year ... 2 million people and kill about 23,000, according ...
Breaking Medicine News(10 mins):Health News:Top 10 Best SEO Hosting Announces That GreenGeeks.com And HostMonster Are Among The Most Reliable Linux Web Hosting Companies In 2014 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... infected with HIV in the UK rose last year to ... not know they are carrying the disease, a report said ... and nearly three-quarters of those were probably contracted in Africa., ... HIV sufferers had risen last year from an estimated 53,000 ...
... of anti-depressant medication and lifestyle change may be it is ... enjoy a splendid ride with a dolphin to help ease ... of biophilia that illustrates the dependence of human health on ... patients with mild to moderate depression were chosen for the ...
... Scientific Advisory Committee on Nutrition in the UK has said ... born with birth defects if folic acid were to be ... reducing commonly found neural tube defects like the spina bifida. ... be avoided if this simple precaution were to be taken. ...
... A new study reveals that antibiotics if taken limitlessly ... more than 10 times during childhood can increase the ... lymphatic system. , The study, conducted by Ellen ... Centre in Fremont, also found heavy use of non-steroidal ...
... its toll on Hong Kong teachers, with one in three ... ,Shouting at students in the class is affecting the ... said dry throats and husky and harsh voices were among ... developed voices like men., ,Researchers claim the problem ...
... Bacteria have been long regarded as something, only capable ... might soon change.// Thanks to the fervent efforts of ... UCSF who have created the first-ever bacterial photographs. ... at promoting the construction of simple biological machines is ...
Cached Medicine News:Health News:Swimming With Dolphins Can Help Ease Depression 2Health News:Bacterial Photographs Created By Student Scientists! 2
... watt halogen light source with ... ,SOLOS Endoscopy shares your commitment ... the highest quality care available ... development of advanced surgical instruments ...
Linvatecs single CCD camera heads offer high resolution with the convenience of programmable buttons for sterile field control of the printer and VCR. Available in "V and "C mount in NTSC and PAL....
... camera system offers the latest technology ... controller. Equipped with many of the ... expensive camera controllers, including edge enhancement, ... The controller is compatible and interchangeable ...
... Camera Systems provide the advanced functionality ... need for advanced training. Programmable, easy ... the flexibility needed to accommodate the ... Compatible with both autoclavable and non-autoclavable ...
Medicine Products: